Zacks Investment Research lowered shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Separately, ValuEngine upgraded Chimerix from a strong sell rating to a sell rating in a research report on Wednesday, October 11th.

Shares of Chimerix (NASDAQ:CMRX) traded down $0.02 during trading on Tuesday, reaching $4.86. The company had a trading volume of 255,811 shares, compared to its average volume of 291,514. The stock has a market capitalization of $229.98, a price-to-earnings ratio of -3.40 and a beta of 1.46. Chimerix has a 52 week low of $4.17 and a 52 week high of $6.64.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. equities research analysts expect that Chimerix will post -1.6 EPS for the current year.

In other news, insider Linda M. Richardson sold 19,833 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.40% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMRX. Voya Investment Management LLC boosted its position in shares of Chimerix by 18.3% during the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 4,526 shares during the period. State of Wisconsin Investment Board purchased a new position in shares of Chimerix during the second quarter worth $185,000. The Manufacturers Life Insurance Company boosted its position in shares of Chimerix by 8.3% during the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 3,042 shares during the period. Rhumbline Advisers boosted its position in shares of Chimerix by 7.3% during the second quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 3,300 shares during the period. Finally, Nationwide Fund Advisors boosted its position in shares of Chimerix by 70.3% during the third quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 24,994 shares during the period. Institutional investors and hedge funds own 70.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/chimerix-cmrx-stock-rating-lowered-by-zacks-investment-research/1801957.html.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.